Rosacea. Systemic therapy with retinoids
Systemic isotretinoin has been known for decades as an effective and safe therapeutic option in the treatment of severe and refractory forms of rosacea. It can also be used in special treatment-resistant forms of rosacea, e.g. granulomatous rosacea, as efficacious second-line therapy. Previously, the effect of isotretinoin in rosacea has been mainly studied in small cohorts or anecdotal reports. Recently, a big randomized double-blind dose-response and comparative study revealed that an optimized dosage of 0,3 mg/kg was superior to other dosages and non-inferior to doxycycline as gold standard of systemic rosacea treatment and proved effective and safe in papulopustular and phymatous subtypes. However, the substance is still not licensed for this indication The efficacy of isotretinoin in rosacea is probably mainly related to anti-inflammatory mechanisms as well as anti-oxidative, anti-angiogenic and antifibrotic properties. The classical antiseborrheic effect of isotretinoin might play a role in special subtypes like the phymatous type or rosacea fulminans.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - 62(2011), 11 vom: 20. Nov., Seite 820-7 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Rosazea. Systemische Therapie mit Retinoiden |
|---|
| Beteiligte Personen: |
Thielitz, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dermatologic Agents |
|---|
| Anmerkungen: |
Date Completed 02.04.2012 Date Revised 20.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00105-011-2144-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM212388932 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM212388932 | ||
| 003 | DE-627 | ||
| 005 | 20231224015435.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2011 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00105-011-2144-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0708.xml |
| 035 | |a (DE-627)NLM212388932 | ||
| 035 | |a (NLM)22015849 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Thielitz, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rosacea. Systemic therapy with retinoids |
| 246 | 3 | 3 | |a Rosazea. Systemische Therapie mit Retinoiden |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.04.2012 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Systemic isotretinoin has been known for decades as an effective and safe therapeutic option in the treatment of severe and refractory forms of rosacea. It can also be used in special treatment-resistant forms of rosacea, e.g. granulomatous rosacea, as efficacious second-line therapy. Previously, the effect of isotretinoin in rosacea has been mainly studied in small cohorts or anecdotal reports. Recently, a big randomized double-blind dose-response and comparative study revealed that an optimized dosage of 0,3 mg/kg was superior to other dosages and non-inferior to doxycycline as gold standard of systemic rosacea treatment and proved effective and safe in papulopustular and phymatous subtypes. However, the substance is still not licensed for this indication The efficacy of isotretinoin in rosacea is probably mainly related to anti-inflammatory mechanisms as well as anti-oxidative, anti-angiogenic and antifibrotic properties. The classical antiseborrheic effect of isotretinoin might play a role in special subtypes like the phymatous type or rosacea fulminans | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Dermatologic Agents |2 NLM | |
| 650 | 7 | |a Isotretinoin |2 NLM | |
| 650 | 7 | |a EH28UP18IF |2 NLM | |
| 700 | 1 | |a Gollnick, H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete |d 1952 |g 62(2011), 11 vom: 20. Nov., Seite 820-7 |w (DE-627)NLM000041157 |x 1432-1173 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2011 |g number:11 |g day:20 |g month:11 |g pages:820-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00105-011-2144-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2011 |e 11 |b 20 |c 11 |h 820-7 | ||